Blood Test Predicts Long-Term Cognitive Function After Cardiac Arrest

Why It Matters

Early detection of brain injury risk after cardiac arrest can streamline resource allocation, improve patient‑family communication, and potentially enhance long‑term outcomes while avoiding unnecessary tests.

Key Takeaways

• NfL measured 48 hours predicts long‑term cognitive outcomes
• Neuron‑specific enolase showed no correlation with future cognition
• Early NfL testing could prioritize imaging and rehab resources
• Assay standardisation required before routine clinical adoption
• Families gain clearer expectations for survivor recovery trajectories

Pulse Analysis

Cardiac arrest remains a leading cause of acute brain injury, and clinicians have long relied on neuron‑specific enolase (NSE) to gauge neuronal damage. However, NSE’s lack of specificity—being influenced by hemolysis, tumor activity, and other systemic factors—has limited its prognostic value. In this context, the search for a more precise biomarker has intensified, especially as hospitals seek to allocate intensive neuro‑imaging and rehabilitation resources efficiently. The emergence of neurofilament light chain (NfL) as a blood‑based indicator offers a promising alternative, reflecting direct axonal disruption rather than indirect metabolic stress.

The ESC Acute Cardiovascular Care 2026 study examined patients from the BOX trial, measuring NfL and NSE 48 hours post‑resuscitation. Researchers discovered a robust inverse relationship between NfL concentrations and Montreal Cognitive Assessment scores obtained months later, establishing NfL as a strong predictor of lasting cognitive impairment. In contrast, NSE levels showed no statistically significant link to cognitive outcomes. This differential performance underscores NfL’s superior specificity for structural neuronal injury, positioning it as a potential early‑warning tool while patients remain comatose and before definitive neuroimaging can be performed.

Adopting routine NfL testing could reshape post‑arrest care pathways. Clinicians would be able to triage high‑risk individuals for advanced imaging, tailor intensive rehabilitation programs, and provide families with realistic recovery forecasts, thereby reducing uncertainty and optimizing healthcare expenditures. Nonetheless, widespread implementation hinges on assay standardisation, cost‑effectiveness analyses, and validation across diverse populations. As the evidence base expands, NfL may become a cornerstone of precision medicine in cardiac arrest, aligning diagnostic accuracy with personalized therapeutic strategies.